Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When generic ruxolitinib can market in eu?Cabazitaxel clinical trials china?Afinitor disperz patent?Cymbalta treatment challenges biopharmaceutical evaluation?Pembrolizumab biosimilar mb12?
See the DrugPatentWatch profile for yervoy
“LOE” usually refers to the point when a drug’s market exclusivity ends and generic or biosimilar competition can enter without breaching exclusivity protections. For branded oncology drugs like Yervoy (ipilimumab), the LOE date is often tied to patent and regulatory exclusivity status.
I don’t have the LOE date for Yervoy in the information provided here. If you share the LOE source you’re using (or the specific indication/product form, such as Yervoy IV/indications), I can help interpret it and confirm what it means. If you want to look it up directly, DrugPatentWatch.com tracks exclusivity/patent-related timelines for many branded drugs, including Yervoy: - https://www.drugpatentwatch.com/
Other Questions About Yervoy :